This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.
EMA backs Lundbeck's Brintellix in depression. Drug recommended for approval to treat major depressive episodes in adults. ... In the latest round of EU drug recommendations, Lundbeck won backing for the use of Brintellix in the treatment of adult
Lundbeck buoyed by Brintellix approval in US. FDA gives green light for to Cipralex/Lexapro successor in depression. ... Lundbeck was celebrating yesterday after the FDA approved its new antidepressant Brintellix, a successor to the big-selling
Lundbeck and Takeda submit depression drug for US approval. Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex. ... Lundbeck's plans to find a replacement for its big-selling antidepressant Lexapro/Cipralex continue
All eyes are on the performance of Cipralex successor Brintellix ( vortioxetine) - which was approved at the end of September - along with other recent launches, such as alcoholism therapy Selincro ( nalmefene) and ... Meanwhile, Selincro's first launch (
Meanwhile, the start of the pivotal trials programme is another fillip for Lundbeck, which passed a major milestone last month when it won US approval for its new antidepressant Brintellix ( vortioxetine).
bring much-vaunted new antidepressant Brintellix ( vortioxetine) to market. ... Brintellix has already been submitted for approval in the EU and the US ( where it will be co-marketed by Takeda) and could achieve sales of $500m within three years of
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.